Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice

Journal of Drug Targeting

Volumn 16, Issue 4, 2008, Pages 302-310

  Shahiwala, Aliasgar ^a   Amiji, Mansoor M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Intranasal administration; Oral administration; Ovalbumin; Squalane oil; Systemic immunity; Water in oil in water (W O W) multiple emulsions

Indexed keywords

CHITOSAN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; OVALBUMIN; POLYSORBATE 80; SORBITAN OLEATE; WATER OIL CREAM;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EMULSION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; CHITOSAN; DRUG CARRIERS; ELECTROCHEMISTRY; EMULSIONS; FEMALE; IMMUNITY; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEUTROPHILS; OVALBUMIN; PARTICLE SIZE; SQUALENE; SUSPENSIONS; WATER;

EID: 43049139895     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860801900082     Document Type: Article

References (51)

1. Almeida, AJ and Alpar, HO (1996) Nasal delivery of vaccines. J Drug Target, 3, pp. 455-467.
2. Anderson, AO (1990) Structure and organization of the lymphatic system, Oxford University Press, New York
3. Barchfeld, GL, Hessler, AL, Chen, M., Pizza, M., Rappuoli, R. and Van Nest, GA (1999) The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine, 17, pp. 695-704.
4. Bonanni, P. (1999) Demographic impact of vaccination: A review. Vaccine, 17, pp. S120-S125.
5. Bowersock, TL, HogenEsch, H., Torregrosa, S., Borie, D., Wang, B., Park, H. and Park, K. (1998) Induction of pulmonary immunity in cattle by oral administration of ovalbumin in alginate microspheres. Immunol Lett, 60, pp. 37-43.
6. Bowersock, TL, HogenEsch, H., Suckow, M., Guimond, P., Martin, S., Borie, D., Torregrosa, S., Park, H. and Park, K. (1999) Oral vaccination of animals with antigens encapsulated in alginate microspheres. Vaccine, 17, pp. 1804-1811.
7. Cataldo, DM and Van Nest, G. (1997) The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine, 15, pp. 1710-1715.
8. Chen, H., Torchilin, V. and Langer, R. (1996) Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm Res, 13, pp. 1378-1383.
9. Chen, SC, Jones, DH, Fynan, EF, Farrar, GH, Clegg, JC, Greenberg, HB and Herrmann, JE (1998) Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol, 72, pp. 5757-5761.
10. Chu, TC, Twu, KY, Ellington, AD and Levy, M. (2006) Aptamer mediated siRNA delivery. Nucleic Acids Res, 34, p. e73.
11. Cunningham, CK, Wara, DW, Kang, M., Fenton, T., Hawkins, E., McNamara, J., Mofenson, L., Duliege, AM, Francis, D., McFarland, EJ and Borkowsky, W. (2001) Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis, 32, pp. 801-807.
12. Davis, SS (2001) Nasal vaccines. Adv Drug Deliv Rev, 51, pp. 21-42.
13. de Haan, A., Geerligs, HJ, Huchshorn, JP, van Scharrenburg, GJ, Palache, AM and Wilschut, J. (1995) Mucosal immunoadjuvant activity of liposomes: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine, 13, pp. 155-162.
14. Doucet, O., Ferrero, L., Garcia, N. and Zastrow, L. (1998) O/W emulsion and W/O/W multiple emulsions: Physical characterization and skin pharmacokinetic comparison in the delivery process of caffeine. Int J Cosmet Sci, 20, pp. 283-295.
15. Dupuis, M., Murphy, TJ, Higgins, D., Ugozzoli, M., van Nest, G., Ott, G. and McDonald, DM (1998) Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol, 186, pp. 18-27.
16. Ferreira, LAM, Doucet, J., Seiller, M., Grossiord, JL, Marty, JP and Wepierre, J. (1995) In vitro percutaneous absorption of etronidazole and glucose: Comparison of O/W, W/O/W and W/O systems. Int J Pharm, 121, pp. 169-179.
17. Gallarate, M., Carlotti, ME, Trotta, M. and Bovo, S. (1999) On the stability of ascorbic acid in emulsified systems for topical and cosmetic use. Int J Pharm, 188, pp. 233-241.
18. Glueck, R. (2001) Review of intranasal influenza vaccine. Adv Drug Deliv Rev, 51, pp. 203-211.
19. Heineman, TC, Clements-Mann, ML, Poland, GA, Jacobson, RM, Izu, AE, Sakamoto, D., Eiden, J., Van Nest, GA and Hsu, HH (1999) A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine, 17, pp. 2769-2778.
20. Higgins, DA, Carlson, JR and Van Nest, G. (1996) MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine, 14, pp. 478-484.
21. Holmgren, J. and Czerkinsky, C. (2005) Mucosal immunity and vaccines. Nat Med, 11, pp. S45-S53.
22. Hori, M., Onishi, H. and Machida, Y. (2005) Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system. Int J Pharm, 297, pp. 223-234.
23. Jones, N. (2001) The nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev, 51, pp. 5-19.
24. Kahn, JO, Sinangil, F., Baenziger, J., Murcar, N., Wynne, D., Coleman, RL, Steimer, KS, Dekker, CL and Chernoff, D. (1994) Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis, 170, pp. 1288-1291.
25. Kunisawa, J., Okudaira, A., Tsutusmi, Y., Takahashi, I., Nakanishi, T., Kiyono, H. and Mayumi, T. (2000) Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses. Vaccine, 19, pp. 589-594.
26. Langenberg, AG, Burke, RL, Adair, SF, Sekulovich, R., Tigges, M., Dekker, CL and Corey, L. (1995) A recombinant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity [corrected]. Ann Intern Med, 122, pp. 889-898.
27. Lehr, CM, Bouwstra, JA, Bodde, HE and Junginger, HE (1992) A surface energy analysis of mucoadhesion: Contact angle measurements on polycarbophil and pig intestinal mucosa in physiologically relevant fluids. Pharm Res, 9, pp. 70-75.
28. Lombry, C., Marteleur, A., Arras, M., Lison, D., Louahed, J., Renauld, JC, Preat, V. and Vanbever, R. (2004) Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice. Pharm Res, 21, pp. 127-135.
29. Mestecky, J., Moldoveanu, Z., Michalek, SM, Morrow, CD, Compans, RW, Schafer, DP and Russell, MW (1997) Current options for vaccine delivery systems by mucosal routes. J Control Release, 48, pp. 243-257.
30. Morishita, M., Matsuzawa, A., Takayama, K., Isowa, K. and Nagai, T. (1998) Improving insulin enteral absorption using water-in-oil-in-water emulsion. Int J Pharm, 172, pp. 189-198.
31. Nitayaphan, S., Khamboonruang, C., Sirisophana, N., Morgan, P., Chiu, J., Duliege, AM, Chuenchitra, C., Supapongse, T., Rungruengthanakit, K., deSouza, M., Mascola, JR, Boggio, K., Ratto-Kim, S., Markowitz, LE, Birx, D., Suriyanon, V., McNeil, JG, Brown, AE and Michael, RA (2000) A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais. AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine, 18, pp. 1448-1455.
32. O'Hagan, DT (2001) Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord, 1, pp. 273-286.
33. O'Hagan, DT, Ott, GS and Van Nest, G. (1997) Recent advances in vaccine adjuvants: The development of MF59 emulsion and polymeric microparticles. Mol Med Today, 3, pp. 69-75.
34. Okochi, H. and Nakano, M. (1996) Basic studies on formulation, method of preparation and characterization of water-in-oil-in-water type multiple emulsions containing vancomycine. Chem Pharm Bull, 44, pp. 180-186.
35. Okochi, H. and Nakano, M. (2000) Preparation and evaluation of W/O/W type emulsions containing vancomycin. Adv Drug Deliv Rev, 45, pp. 5-26.
36. Omotosho, JA, Whateley, TL and Florence, AT (1989) Release of 5-fluorouracil from intramuscular W/O/W multiple emulsions. Biopharm Drug Dispos, 10, pp. 257-268.
37. Omotosho, JA, Florence, AT and Whateley, TL (1990) Absorption and lymphatic uptake of 5-fluorouracil in the rat following oral administration of W/O/W multiple emulsions. Int J Pharm, 61, pp. 51-56.
38. Pass, RF, Duliege, AM, Boppana, S., Sekulovich, R., Percell, S., Britt, W. and Burke, RL (1999) A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis, 180, pp. 970-975.
39. Raynal, S., Grossiord, JL, Seiller, M. and Clausse, D. (1993) A topical W/O/W multiple emulsion containing several active substances: Formulation, characterization and study of release. J Control Release, 26, pp. 129-140.
40. Sally, B., Ronald, BM and Eduardo, F-C (2003) Calculating the potential epidemic-level impact of therapeutic vaccination on the San Francisco HIV epidemic. AIDScience, 3
41. Silva-Cunha, A., Chéron, M., Grossiord, JL, Puisieux, F. and Seiller, M. (1998) W/O/W multiple emulsions of insulin containing a protease inhibitor and an absorption enhancer: Biological activity after oral administration to normal and diabetic rats. Int J Pharm, 169, pp. 33-44.
42. Silva-Cunha, A., Grossiord, JL and Seiller, M. (1999) Multiple emulsions: Pharmaceutical potentiality. Multiple emulsions: Structure, properties and applications, pp. 279-312. de Sante, France
43. Soane, RJ, Frier, M., Perkins, AC, Jones, NS, Davis, SS and Illum, L. (1999) Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm, 178, pp. 55-65.
44. Swart, PJ, Beljaars, L., Kuipers, ME, Smit, C., Nieuwenhuis, P. and Meijer, DK (1999) Homing of negatively charged albumins to the lymphatic system: General implications for drug targeting to peripheral tissues and viral reservoirs. Biochem Pharmacol, 58, pp. 1425-1435.
45. Tabata, Y., Inoue, Y. and Ikada, Y. (1996) Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine, 14, pp. 1677-1685.
46. Traquina, P., Morandi, M., Contorni, M. and Van Nest, G. (1996) MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis, 174, pp. 1168-1175.
47. Uchida, T. and Goto, S. (1994) Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: Particle size study. Biol Pharm Bull, 17, pp. 1272-1276.
48. Uchida, T., Martin, S., Foster, TP, Wardley, RC and Grimm, S. (1994) Dose and load studies for subcutaneous and oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin. Pharm Res, 11, pp. 1009-1015.
49. van der Lubben, IM, Verhoef, JC, Borchard, G. and Junginger, HE (1996) Chitosan for immunogenicity of influenza vaccine in both young and old mice. Vaccine, 14, pp. 478-484.
50. Verschoor, EJ, Mooij, P., Oostermeijer, H., van der Kolk, M., Haaft, P ten, Verstrepen, B., Sun, Y., Morein, B., Akerblom, L., Fuller, DH, Barnett, SW and Heeney, JL (1999) Comparison of immunity generated by nucleic acid-, MF59- and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: Evidence for viral clearance. J Virol, 73, pp. 3292-3300.
51. Watarai, S., Han, M., Tana and Kodama, H. (1998) Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes. J Vet Med Sci, 60, pp. 1047-1050.